42 results about "Poxvirus Infections" patented technology

The present invention provides methods of inhibiting orthopoxvirus replication and / or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are particularly useful as inhibitors of vaccinia virus and variola virus replication and / or for the treatment of vaccinia virus and variola virus infection. The nucleoside compounds may be administered alone or in combination with other agents active against orthopoxvirus infection, in particular against vaccinia virus or variola virus infection. Another aspect of the present invention provides for the use of such nucleoside compounds in the manufacture of a medicament for the inhibition of orthopoxvirus replication and / or for the treatment of orthopoxvirus infection. Yet a further aspect of the present invention provides such nucleoside compounds for use as a medicament for the inhibition of orthopoxvirus replication and / or for the treatment of orthopoxvirus infection.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.

Herein is described a system to combat poxvirus infection wherein antagonists are developed that bind the soluble cytokine receptor but have no significant biological activity in the host, effectively blocking the virus-mediated suppressor of interferon function, thereby permitting the host's own cytokines to stimulate an antiviral response. Alternatively, interferon molecules can be developed that retain biological activity on their native receptors but fail to bind the viral cytokine binding protein, thereby circumventing this virus immune modulation mechanism.

The invention discloses a hybridoma cell line K3L25. The preservation number of the hybridoma cell line K3L25 in China Center for Type Culture Collection (CCTCC) is CCTCC NO: C2015222. The hybridoma cell line K3L25 and the monoclonal antibody secreted by the hybridoma cell line K3L25 show good immunogenicity, and can be applied in preparation of an early diagnosis reagent or a reagent for early diagnosing sheeppox virus infection or a reagent for basic tests.

This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula XVII which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and / or its interaction with its processivity factor. Formula XVII can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

The invention discloses a bioactive preparation of a specific anti-variola virus infection model strain and application of the bioactive preparation. The bioactive preparation CH2009 is specifically applied to (1) preparation of products for inhibiting poxvirus infection or (2) inhibition of poxvirus infection. The bioactive preparation CH2009 with a specific anti-poxvirus infection function is prepared from inflammatory skin tissues of a New Zealand white rabbit through the steps of high temperature and high pressure treatment, solvent extraction, acid and alkali treatment, adsorption, elution, centrifugal concentration and the like by utilizing intracutaneous inoculation of poxviruses on the New Zealand white rabbit. The invention provides a brand-new design strategy for research and development of new-generation drugs for resisting infection of poxviruses, such as variola; and the obtained antiviral drug certainly has wide application prospects and huge commercial values.

The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and / or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.

Belonging to the technical field of virology and genetic engineering, the invention discloses a preparation method of a viral vaccine expressing plasmodium ovale AMA1 protein. According to the invention, a gene expressing plasmodium ovale apical membrane protein-1 is inserted into a vesicular stomatitis virus VSV genome vector to construct the recombinant virus vector skeleton plasmid XN2-AMA1, apoxvirus containing T7RNA polymerase is employed to infect the baby hamster kidney cell (BHK-21), then the plasmid XN2-AMA1 and the structural protein plasmids pN, pP, pL are utilized for cotransfection of BHK-21 cells to realize rescue of recombinant virus in cells, virus-like particles expressing AMA1 are packaged, and the recombinant virus rVSV-AMA1, i.e. the vaccine can be formed. The vaccineprovided by the invention has the advantages of simple operation, high production titer and short immune cycle, can induce strong humoral and cellular immune response, and has the great potential of clinical application.

Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.

This invention provides compounds of formulas (I), (II), (III), and (IV) as defined in the specification, and pharmaceutical compositions comprising the same, and methods of inhibiting, treating, or abrogating a poxvirus infection in a subject using the compounds or compositions.

The present invention provides methods of treating diseases associated with at least one virus. The methods include administering a compound described in the invention in a therapeutically effective amount. According to some aspects of the present invention, the methods provide treatment of an orthopox virus infection or a disease related to orthopox virus.

Described herein is a novel method for generation of recombinant poxviruses using an E3 and K3 double deletion mutant virus as the parental virus for generation of recombinant viruses. Following allowing for crossing over between the parental virus and an insertion cassette including an orthopox K3 peptide and the gene of interest, recombinant viruses are selected by infecting a host cell line permissive for the orthopox K3 peptide but not for the E3 and K3 double mutant parental virus. It is also demonstrated that a specific small molecule inhibitor of NEDD8 activating enzyme, MLN4924, can completely block poxvirus K3 family protein mediated PKR degradation and virus replication.

The invention discloses a bioactive preparation and application of a specific anti-smallpox virus infection model strain. The application provided by the present invention is specifically the application of the bioactive preparation CH2009 in the following (1) or (2): (1) preparing a product for inhibiting poxvirus infection; (2) for inhibiting poxvirus infection; The biologically active preparation CH2009 is prepared from the inflammatory skin tissue of New Zealand white rabbits by intradermally inoculating vaccinia virus, high temperature and high pressure, solvent extraction, acid-base treatment, adsorption, elution, and centrifugal concentration. Bioactive agents specific for poxvirus infection. The present invention provides a new design strategy for the research and development of a new generation of anti-pox virus infection drugs such as smallpox, and the obtained anti-viral drugs undoubtedly have broad application prospects and huge commercial value.

The invention discloses an anti-pigeon pox traditional Chinese medicine composition, which comprises the following components in parts by weight: 25-45 parts of kudzu root, 25-45 parts of forsythia, 20-35 parts of Cimicifuga, 20-35 parts of Smilax cocos, Qu Mai 20-35 parts, 15-30 parts of honeysuckle, 15-30 parts of licorice. The invention also discloses a preparation method of the oral liquid of the anti-pox traditional Chinese medicine composition. In the present invention, the use of traditional Chinese medicines instead of western medicines for pigeon pox virus infection can reduce or eliminate drug residues in poultry meat and eggs, thereby facilitating the pollution-free production of livestock products; and can be widely used in the treatment of various poultry including pigeons Pox virus infection: Pigeons suffering from pox virus infection can obtain significant curative effect by using this product, and the cure rate is over 95%. Especially for the pox scabs, they will fall off and heal within one week after medication, and will not recur.